March 12, 2020
Harbour BioMed raises a $75,000,000 series B round from SK Holdings.
Harbour BioMed raises a $85,000,000 series B round from Advantech Capital, China Life Private Equity Investment Co, GIC Private Limited, Legend Capital and Vertex Ventures.
Documentaries, videos and podcasts
June 17, 2021
/PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced the dosing of the first patient of HBM4003 in patients with advanced non-small cell lung...
June 16, 2021
The research collaboration will see the development of bispecific antibodies and CAR-T cell products.
June 16, 2021
/PRNewswire/ -- Harbour BioMed (HKEX: 02142) announced today it has entered into a multi-year, multifaceted research collaboration agreement with Dana-Farber...
May 11, 2021
/PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced the dosing of the first patient in its part 2 of phase I (phase Ib/IIa) clinical study of...
February 26, 2021
/PRNewswire/ -- Harbour BioMed (HBM) (HKEX: 02142) today announced that the China National Medical Products Administration (NMPA) has approved its...
December 17, 2020
/PRNewswire/ -- HBM Holdings Limited ("Harbour BioMed", "HBM" or the "Company"; Stock Code: 02142.HK), a global clinical-stage biopharmaceutical company,...
Global Market Insights, Inc.
November 9, 2020
/PRNewswire/ -- According to the latest report "Animal Model Market Animal Type (Mice, Rats, Fish, Birds, Cattles, Pigs, Amphibians, Guinea Pigs, Dogs, Cats,...
By Jonathan Chadwick For Mailonline
May 4, 2020
Scientists say they've discovered an antibody that blocks infection by SARS-CoV-2, the coronavirus behind the current global health crisis.
May 5, 2019
CAMBRIDGE, Mass., ROTTERDAM, Netherlands, and SHANGHAI, May 5, 2019 /PRNewswire/ -- Harbour BioMed and Chia Tai Tianqing Pharmaceutical Group Ltd. (CTTQ) today ...